SlideShare a Scribd company logo
MALARIA
Learning objective
 Definition of malaria and types of malaria parasites
 Epidemiology of malaria
 Risk factor of malaria
 Life cycle of malaria
 Incubation period of the parasite
 Pathophysiology of malaria
 Signs and symptoms of malaria
 Laboratory diagnosis of malaria
 Treatment and prevention of malaria
 Complication of malaria
What is malaria ?
• Malaria is a serious or life threatening disease that
spreads when you’re bitten by a Anopheles mosquito
infected by tiny parasites. When it bites, the
mosquito injects malaria parasites into your
bloodstream. Malaria is caused by the parasites, not
by a virus or by a type of bacterium.
• If it isn’t treated, malaria can cause severe health
problems such as seizures, brain damage, trouble
breathing, organ failure and death.
Cont…
• Is an infection of liver and RBCs caused by
protozoan parasites of the genus plasmodium.
Malaria is caused by 5 species of plasmodium:
• P. falciparum (the most common and dangerous).
• P. vivax (the most common)
• P. ovale
• P. malariae
• P. knowlesi
Epidemiology
• It is reported that Plasmodium vivax is more
prevalent in India, Pakistan, Bangladesh, Sri Lanka,
and Central America,
• whereas Plasmodium falciparum is predominant in
Africa, Haiti, Dominican Republic, the Amazon region
of South America, and New Guinea.
• Most of the infections with Plasmodium ovale occur
in Africa, and the distribution of Plasmodium
malariae is considered worldwide.
Cont…
• The commonest causes of malaria in Ethiopia are
Plasmodium falciparum and Plasmodium vivax. P.
falciparum causes virtually all the severe forms
of malaria.
• More than 50% of the total population in
Ethiopia is exposed to the risk of malaria
infection. Every year, four to five million people
are affected by malaria while a major epidemic
occurs every five to eight years.
Risk factor for malaria
• Living or traveling in a region where malaria is
present.
• Traveling to area where malaria is common: -
Without taking medicine to prevent malaria.
- Being outdoors, especially in rural areas
- Not taking steps to protect yourself from
mosquito bites.
• Pregnant women.
• Children under 5 years of age.
• Patients with HIV/AIDS.
Lifecycle of Plasmodium
• 2 stages
1) Sexual phase in the mosquito – sporogony
2) Asexual phase in humans
A, Exoerthrocytic phase ( liver stage )
B, Erythrocytic phase ( blood stage )
• The infectious stage of malaria - Sporozoite (found in
the salivary glands of female mosquitoes).
Exoerthrocytic Phase
• Sporozoites enters the hepatocytes and become
merozoites . Merozoites replicates asexually forming
a schizont which eventually bursts.
• In p. ovale and p. vivax, some sporozoites do not
undergo asexual replication and enter a dormant
phase known as hypnozoites which reactivate later
resulting in a relapse.
Erythrocytic Phase
• Merozoites release from hepatocytes invade
erythrocytes, undergoes a trophic period then
replicates in it asexually.
• It later bursts releasing merozoites which infect more
cells.
• The release of merozoites is what causes malarial
paroxyms.
Sporogony
• Trophozites in RBC’s undergo a sexual cycle which
differentiates into gametocytes and are then
ingested by a mosquito.
• In the mosquito: Gametocytes become gametes
which fuse to become a zygote in the mosquitos gut
which then develops into an ookinete then into an
oocyte.
• The oocyte divides asexually, ruptures and releases
sporozoites which infects the salivary gland and is
what is injected into the host.
Incubation period
• Following the infective bite by the Anopheles
mosquito, a period of time (the “incubation period”)
goes by before the first symptoms appear. The
incubation period in most cases varies from 7 to 30
days.
Incubation period of the parasite
SPECIES INCUBATION PERIOD ( LIVER CYCLE )
P. falciparum 7-14 days
p. vivax 12-17 days( with relapse up to 3years )
p. ovale 9-18 days ( with relapse up to 20 years
p. malaria 13-40 days
Cont..
• The time between the fever episodes can be characteristics of
the infecting plasmodium species
SPECIES Duration of fever (erythrocytic cycle
)
P. falciparum 36-48hr, Malignant tertian fever
p. vivax 48hr, Benign tertian fever
p. ovale 48hr, Ovale tertian fever
p. malaria 72hr, Quartan fever
Pathophysiology of malaria
• New merozoites are released from the RBCs at
intervals of approximately 48h for P.vivax, P.ovale and
P.falciparum and 72h for P.malaria. The episodic
shaking, chills, and fever coincide with this release.
• The parasites destroy large numbers of infected RBC,
thereby causing a hemolytic anemia.
Cont..
• A characteristic brown malaria pigment derived from
hemoglobin, called hemozoin is released from
ruptured RBCs and produces discoloration of the
spleen, liver, lymph nodes and bone marrow.
• Activation of defense mechanisms in the host leads
to a marked hyperplasia of mononuclear phagocytes,
producing massive splenomegaly and occasional
hepatomegaly.
Common symptoms
• High temperature 38c or above
• Feeling hot or shivery
• Headaches
• Vomiting
• Diarrhea
• Muscle pain
• Generally feeling unwell
CLINICAL FEATURE OF
UNCOMPLICATED MALARIA
• Fever, chills, rigors, sweating
• Headache, generalized body and joint pain
(myalgia and arthralgia)
• Nausea and/or vomiting, loss of appetite,
abdominal pain (especially in children)
• Irritability and refusal to feed (in infants), flu-like
symptoms,
• Fever, usually above 38°C
• hepatosplenomegaly
INVESTIGATIONS AND DIAGNOSIS
Investigations
• Microscopy-thick and thin blood films for malaria
parasites
• Rapid diagnostic tests (RDT)-if microscopy is unavailable
• CBC
Diagnosis
• The diagnosis of malaria can be confirmed when malaria
parasites are demonstrated in the blood films (thick or
thin) or with Rapid Diagnostic Test (RDT).
Cont..
• Blood film is also helpful to estimate the degree of
parasitemia, which is very useful not only to predict
severity but gauge response to treatment.
• If neither microscopy nor rapid tests are available,
diagnosis should be made on the basis of clinical
presentation.
• Clinical diagnosis of malaria is made in a patient who has
fever or history of fever in the past 48 hours and lives in
malaria-endemic areas or has a history of travel within
the last 30 days to malaria-endemic areas
Treatment
Objectives
• Prevent uncomplicated malaria from progressing
to severe form
• Improve societal productivity
• Prevent death from malaria complication
• Prevent the development and transmission of
drug resistance
• Decrease malaria transmission to others
SUPPORTIVE TREATMENT FOR
UNCOMPLICATED MALARIA
• Fever management (axillary temp record of ≥37.50C)
Antipyretics
− Paracetamol (acetaminophen) 15 mg/kg (for adults
1000mg) every 4-6 hours, given orally or as a suppository.
Fanning and tepid sponging
• Check for signs of severity
• Assess the ability to tolerate oral medication.
• If there is any sign of severity or the patient is unable to
tolerate oral medications admit patients for parenteral
treatment.
PHARMACOLOGIC
• P. falciparum:
First line:Artemether +Lumefantrine(AL), fixed dose
combination
(20mg + 120mg) for 3 days + a single dose
primaquine phosphate (15mg base P.O).
• First line for pregnant women in the first trimester:
quinine
Cont..
• P. vivax
o Chloroquine phosphate 25 mg/kg given in divided doses
over three days
− 1 g (4 tablets) initially, then 500mg (2tablets) in 6 hours, it is
then followed by 500mg (2ablets), PO, daily for 2 days.
OR
− 1g (4 tablets) at 0 and 24 hours. It is followed by 500mg (2
tablets) at 48 hrs.
o Primaquine phosphate 15mg base, PO, daily for 14 days for
all patients after completing the three days of chloroquine.
Mixed infections (P. falciparum and P. vivax)
• Artemisinin based combination therapies (like AL for
3 days) should be used for mixed (falciparum and
vivax) infections, followed by 14-day primaquine
phosphate.
• Avoid primaquine in pregnant, breast-feeding
mothers less than 6 months infants, infants under six
months of age.
TREATMENT FAILURE
• Consider treatment failure in a patient with malaria who
was treated for malaria in the past 28 days.
• The cause might be drug resistance, poor adherence or
inadequate drug exposure (i.e. from under-dosing,
vomiting, drug interaction, misdiagnosis
or substandard medicines.
• If the cause for treatment failure identified early (e.g.
anti-malarial drug is vomited), address the cause and
reinstituted treatment with the first line anti-malarial
drug;
Cont…
• If a P. falciparum or P. vivax-infected patient returns
with fever or history of fever between days 4 to 28 of
treatment, microscopic blood examination should be
made (do not use RDTs).
• If parasites are detected, administer second-line
drug, e.g., quinine tablets;
• If blood smear is negative and no other obvious
causes found, reevaluate,or refer
• For treatment failure after 28 days, first line
antimalarial drugs should be used.
COMPLICATED (P. FALCIPARUM ) MALARIA
• Delayed presentation, delay in diagnosis or
inappropriate treatment of uncomplicated malaria
can lead to the rapid development of severe or
“complicated malaria”.
• It is commonly occurring in children under 5 years of
age, pregnant women and non-immune individuals.
Severe malaria may lead to death unless it is
diagnosed early and appropriately managed.
CLINICAL FEATURES
• Inability to take in fluids (or breast milk in children)
• Repetitive vomiting
• Dark or ‘cola-colored’ urine/ hemoglobinuria
• Difficulty in breathing ,
• Generalized convulsions,
• Altered consciousness, confusion, delirium, convulsions, coma
• Circulatory collapse or shock (cold limbs, weak rapid pulse)
• Tachypnea, respiratory distress and/or cyanosis
• Hyperpyrexia (axillary temperature >38.5°C)
• Hypoglycemia
• Severe anemia (Hb < 6 g/dl) or extreme pallor (severe anemia)
INVESTIGATIONS AND DIAGNOSIS
Investigation
• Microscopy-thick and thin blood films for malaria
parasites
• Rapid diagnostic test (RDT)-if microscopy is
unavailable
• Hemoglobin, hematocrit, CBC
• Blood glucose (RBS)
• Blood grouping and cross-matching
• BUN and creatinine
Cont..
Diagnosis
• The diagnosis of severe malaria is based on
clinical features and confirmed with
laboratory testing. While confirmation of the
diagnosis is necessary treatment must be
started promptly and not withheld while
confirming the diagnosis.
TREATMENT OF SEVERE AND COMPLICATED P. FALCIPARUM
MALARIA
Objectives
• Administer medicines parenterally to ensure
adequate blood-serum concentrations of the
medicine and rapid clearance of parasitemia
• Provide urgent treatment for life threatening
problems e.g., convulsions, hypoglycemia,
dehydration, renal impairment
• Prevent death from malaria
Cont..
Non pharmacologic
• Clear and maintain the airway.
• Open IV line for 8 hours of intravenous fluids including
diluents for antimalarial medicine, glucose therapy and
blood transfusion.
• Make rapid clinical assessment.
• Weigh the patient and calculate dosage.
• Exclude or treat hypoglycemia (more so in pregnant
women and children).
• Assess state of hydration.
• Measure and monitor urine output.
Pharmacologic
General principles of treatment
o It is a medical emergency.
o Parenteral administration required
(Artesunate >quinine)
o Also involves multiple supportive treatment
measures
First line
• Artesunate, 2.4mg/Kg IV or IM given on admission (time = 0),
then repeat at 12 hours, and 24 hours, then once a day for up to
5 days.
OR
• If artesunate is unavailable: Artemether, IM 3.2mg/kg loading
dose on the first day followed by 1.6mg/kg daily for five days
OR
• If artesunate and artemether are unavailable: Quinine
hydrochloride
 Quinine hydrochloride loading dose: 20mg/kg in 500ml of 5% dextrose
or normal saline over 4 hours (4ml/minute). The pediatric loading dose is
the same but the fluid replacement must be based on body weight.
DOSING GUIDELINES FOR ANTIMALARIAL DRUGS
• Artesunate is dispensed as a powder of Artesunic acid.
• The 60mg vial of artesunate must be reconstituted in two
steps:
First: sodium bicarbonate solution (Provided separately along
with the vial)
Second: with 5ml of 5% glucose (D5W) solution.
• Full reconstitution results in either 6ml (for intravenous use,
with a concentration of 10mg/ml) or 3ml (for intramuscular
injection, with a concentration of 20mg/ml).
HEMATOLOGIC COMPLICATIONS (INCLUDING SEVERE
ANEMIA AND COAGULOPATHY)
Anemia
• Indication for transfusion
− If hematocrit is below 15% (Hg <5g/dl) in a normally hydrated
child or adult.
− Anemia with shock or evidence heart failure, metabolic acidosis
(deep labored breathing or high parasitemia (>20% of RBCs
parasitized)
• Volume of transfusion: 10 ml/Kg of packed RBC or 20 ml whole
blood/ kg of body weight. For adults it is equivalent to 2-3 units of
packed RBC or 2-3 units of whole blood.
• The volume of all blood products should be included in the overall
fluid balance. The patient should be closely monitored during the
blood transfusion.
Cont..
Bleeding tendency:
• Check for evidence of DIC (if laboratory tests are
available): platelet
count, PT/INR, and PTT
Management: Transfusion of platelet and fresh frozen
plasma or fresh whole blood (if platelet and fresh
frozen plasma are not available).
ACUTE RENAL FAILURE (ACUTE KIDNEY INJURY)
• Persistent oliguria, despite adequate correction of
dehydration or hypotension:
o <17 ml/hour in adults (<200ml in 12 hours or <400ml
in 24 hours); <0.3 ml/kg/hour in children.
OR
• Elevated serum creatinine: increase in serum creatinine
more than twice
(two fold) from baseline.
Management: correct dehydration, if there is any evidence of
hypovolemia. Avoid over hydration (fluid overload). If oliguria
persists, refer to a facility with dialysis service.
HYPOGLYCEMIA:
• Suspect in any patient who deteriorates suddenly,
decreased level of consciousness or convulsions.
• Threshold for intervention among children <5 years is <3
mmol/L (<54mg/dl); children ≥5 years and adults are <2.2
mmol/L (<40 mg/dl).
Management
• IV dextrose: initial bolus
− 40% dextrose for children: 1ml/kg/dose, diluted with
equal volume of NS, give slowly to avoid irritation of vein and
extravasation.
− 40% dextrose for adults: 80ml (4 vials of 20ml
preparation) diluted with equal volume of NS, administer
slowly.
NEUROLOGIC COMPLICATIONS (INCLUDE ALTERED
SENSORIUM, SEIZURE, AND COMA):
• Management of convulsions:
o Ensure the patient is in a safe environment to avoid injuries
o Position the patient laterally (sideways) to protect the
airways
o Diazepam
− Children: 0.15 mg/kg body weight IV or 0.5 mg/kg body
rectally
− Adults: 0.15 mg/kg body weight IV (maximum 10 mg)
• Management of coma
o Position the patient on the sides, change positions every 2
hours, correct hypoglycemia and regularly check blood sugar
levels.
Prevention
• Avoid mosquito bites: using mosquito repellants, insectides,
using mosquito nets, wearing long sleeves and trousers and
window screens.
• chemoprophylaxis for travellers and pregnant women. For all
species of Plasmodium is chloroquine phosphate 300 mg
(base) once weekly beginning 1 week prior to departure and
continued for 4 weeks after leaving an endemic area. The
pediatric dose is (5 mg) (base) per kilogram of body weight
(maximum: 300 mg).
If the traveller is going to places where there is a chloroquine
resistance : Mefloquine, 5mg base per kg weekly (1tablet for
adults >50kg, begin > 2weeks before travel to endemic area),
take weekly on the same day while in the area and for 4 weeks
after leaving the area.
Reference
• Dipiro pharmacotherapy : a pathophysiology
approach 7th edition
• Ministry of health - Ethiopian standard
treatment guidelines for general hospital 4th
edition 2021
• Centers for disease control and prevention
(CDC)– about malaria
THANK YOU

More Related Content

What's hot

DENGUE IN CHILDREN
DENGUE IN CHILDRENDENGUE IN CHILDREN
DENGUE IN CHILDREN
apoorvaerukulla
 
Nephrotic Syndrome
Nephrotic SyndromeNephrotic Syndrome
Nephrotic Syndrome
Drhunny88
 
BURKITTS LYMPHOMA
 BURKITTS LYMPHOMA BURKITTS LYMPHOMA
BURKITTS LYMPHOMA
ALIYU USMAN MUHAMMAD
 
Nocturnal enuresis 2019
Nocturnal enuresis 2019Nocturnal enuresis 2019
Nocturnal enuresis 2019
Hussein Abdeldayem
 
Malaria IN Pediatrics
Malaria IN  Pediatrics Malaria IN  Pediatrics
Malaria IN Pediatrics
Drsurajkc
 
Cerebral Malaria
Cerebral Malaria Cerebral Malaria
Cerebral Malaria
Ade Wijaya
 
Cerebral malaria lec
Cerebral malaria  lecCerebral malaria  lec
Cerebral malaria lec
Shakeel Ahmed
 
ACUTE RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE
ACUTE RHEUMATIC FEVER AND RHEUMATIC HEART DISEASEACUTE RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE
ACUTE RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE
Dr. Murtaza Kamal MD,DNB,DrNB Ped Cardiology
 
Malaria in children 2021
Malaria in children 2021Malaria in children 2021
Malaria in children 2021
Imran Iqbal
 
Malaria history and present
Malaria history and presentMalaria history and present
Malaria history and present
Dr. Ramkesh Prasad
 
Nocturnal Enuresis
Nocturnal EnuresisNocturnal Enuresis
Nocturnal Enuresis
Azad Haleem
 
Hyperthyroidism in children
Hyperthyroidism in childrenHyperthyroidism in children
Hyperthyroidism in children
CSN Vittal
 
Typhoid fever in children 2021
Typhoid fever in children 2021Typhoid fever in children 2021
Typhoid fever in children 2021
Imran Iqbal
 
Malaria
MalariaMalaria
Leukemia in Children
Leukemia in ChildrenLeukemia in Children
Leukemia in Children
CSN Vittal
 
Hemangioma
HemangiomaHemangioma
Hemangioma
Milan Kharel
 
Polycystic kidney disease
Polycystic kidney diseasePolycystic kidney disease
Polycystic kidney disease
Muhammad Kamran (Sial)
 
Goodpasture syndrome
Goodpasture syndromeGoodpasture syndrome
Goodpasture syndrome
Deepak Chinagi
 
Immune Thrombocytopenic
Immune ThrombocytopenicImmune Thrombocytopenic
Immune Thrombocytopenic
Eneutron
 
Headache in Children.pptx
Headache in Children.pptxHeadache in Children.pptx
Headache in Children.pptx
Jwan AlSofi
 

What's hot (20)

DENGUE IN CHILDREN
DENGUE IN CHILDRENDENGUE IN CHILDREN
DENGUE IN CHILDREN
 
Nephrotic Syndrome
Nephrotic SyndromeNephrotic Syndrome
Nephrotic Syndrome
 
BURKITTS LYMPHOMA
 BURKITTS LYMPHOMA BURKITTS LYMPHOMA
BURKITTS LYMPHOMA
 
Nocturnal enuresis 2019
Nocturnal enuresis 2019Nocturnal enuresis 2019
Nocturnal enuresis 2019
 
Malaria IN Pediatrics
Malaria IN  Pediatrics Malaria IN  Pediatrics
Malaria IN Pediatrics
 
Cerebral Malaria
Cerebral Malaria Cerebral Malaria
Cerebral Malaria
 
Cerebral malaria lec
Cerebral malaria  lecCerebral malaria  lec
Cerebral malaria lec
 
ACUTE RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE
ACUTE RHEUMATIC FEVER AND RHEUMATIC HEART DISEASEACUTE RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE
ACUTE RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE
 
Malaria in children 2021
Malaria in children 2021Malaria in children 2021
Malaria in children 2021
 
Malaria history and present
Malaria history and presentMalaria history and present
Malaria history and present
 
Nocturnal Enuresis
Nocturnal EnuresisNocturnal Enuresis
Nocturnal Enuresis
 
Hyperthyroidism in children
Hyperthyroidism in childrenHyperthyroidism in children
Hyperthyroidism in children
 
Typhoid fever in children 2021
Typhoid fever in children 2021Typhoid fever in children 2021
Typhoid fever in children 2021
 
Malaria
MalariaMalaria
Malaria
 
Leukemia in Children
Leukemia in ChildrenLeukemia in Children
Leukemia in Children
 
Hemangioma
HemangiomaHemangioma
Hemangioma
 
Polycystic kidney disease
Polycystic kidney diseasePolycystic kidney disease
Polycystic kidney disease
 
Goodpasture syndrome
Goodpasture syndromeGoodpasture syndrome
Goodpasture syndrome
 
Immune Thrombocytopenic
Immune ThrombocytopenicImmune Thrombocytopenic
Immune Thrombocytopenic
 
Headache in Children.pptx
Headache in Children.pptxHeadache in Children.pptx
Headache in Children.pptx
 

Similar to MALARIA.pptx

Malaria-Parasitorology, clinical features, pathogenesis and treatment.pdf
Malaria-Parasitorology, clinical features, pathogenesis and treatment.pdfMalaria-Parasitorology, clinical features, pathogenesis and treatment.pdf
Malaria-Parasitorology, clinical features, pathogenesis and treatment.pdf
Happychifunda
 
Malaria presentation link
Malaria presentation linkMalaria presentation link
Malaria presentation link
Jeevan Jiiva
 
Sovran rai
Sovran raiSovran rai
Sovran rai
Sovranrai1
 
Malaria ppt final
Malaria ppt finalMalaria ppt final
Malaria ppt final
Dr. Nitish kumar
 
Malaria
MalariaMalaria
Malaria
MalariaMalaria
MALARIA by Rohan.pptx
MALARIA by Rohan.pptxMALARIA by Rohan.pptx
MALARIA by Rohan.pptx
SheikWaseem
 
Malaria.pptx
Malaria.pptxMalaria.pptx
Malaria.pptx
LaasyaRatnaPagadala
 
11. INSECT-BORNE DISEASE.pdf
11. INSECT-BORNE DISEASE.pdf11. INSECT-BORNE DISEASE.pdf
11. INSECT-BORNE DISEASE.pdf
YoerdyAgusmalSaputra1
 
Pharmacotherapy of Malaria
Pharmacotherapy of MalariaPharmacotherapy of Malaria
Pharmacotherapy of Malaria
Koppala RVS Chaitanya
 
Malaria PPT 1 NEW.pptx
Malaria PPT 1 NEW.pptxMalaria PPT 1 NEW.pptx
Malaria PPT 1 NEW.pptx
SyedFurqan30
 
Malaria
MalariaMalaria
malaria- pharmacotherapy
malaria- pharmacotherapymalaria- pharmacotherapy
malaria- pharmacotherapy
Aparna Kuntala
 
Arthopod vector borne diseases
Arthopod vector borne diseases Arthopod vector borne diseases
Arthopod vector borne diseases
vinay nandimalla
 
Typhoid Fever - Enteric Fever
Typhoid Fever - Enteric Fever Typhoid Fever - Enteric Fever
Typhoid Fever - Enteric Fever
Mohammed Aljaber
 
Malaria
MalariaMalaria
Malaria ppt.
Malaria ppt.Malaria ppt.
Malaria ppt.
Lajina Ghimire
 

Similar to MALARIA.pptx (20)

8 malaria.pdf
8 malaria.pdf8 malaria.pdf
8 malaria.pdf
 
Malaria-Parasitorology, clinical features, pathogenesis and treatment.pdf
Malaria-Parasitorology, clinical features, pathogenesis and treatment.pdfMalaria-Parasitorology, clinical features, pathogenesis and treatment.pdf
Malaria-Parasitorology, clinical features, pathogenesis and treatment.pdf
 
Malaria presentation link
Malaria presentation linkMalaria presentation link
Malaria presentation link
 
Sovran rai
Sovran raiSovran rai
Sovran rai
 
Malaria ppt final
Malaria ppt finalMalaria ppt final
Malaria ppt final
 
Malaria
Malaria Malaria
Malaria
 
Malaria
MalariaMalaria
Malaria
 
Malaria
MalariaMalaria
Malaria
 
Malar ia10
Malar ia10Malar ia10
Malar ia10
 
MALARIA by Rohan.pptx
MALARIA by Rohan.pptxMALARIA by Rohan.pptx
MALARIA by Rohan.pptx
 
Malaria.pptx
Malaria.pptxMalaria.pptx
Malaria.pptx
 
11. INSECT-BORNE DISEASE.pdf
11. INSECT-BORNE DISEASE.pdf11. INSECT-BORNE DISEASE.pdf
11. INSECT-BORNE DISEASE.pdf
 
Pharmacotherapy of Malaria
Pharmacotherapy of MalariaPharmacotherapy of Malaria
Pharmacotherapy of Malaria
 
Malaria PPT 1 NEW.pptx
Malaria PPT 1 NEW.pptxMalaria PPT 1 NEW.pptx
Malaria PPT 1 NEW.pptx
 
Malaria
MalariaMalaria
Malaria
 
malaria- pharmacotherapy
malaria- pharmacotherapymalaria- pharmacotherapy
malaria- pharmacotherapy
 
Arthopod vector borne diseases
Arthopod vector borne diseases Arthopod vector borne diseases
Arthopod vector borne diseases
 
Typhoid Fever - Enteric Fever
Typhoid Fever - Enteric Fever Typhoid Fever - Enteric Fever
Typhoid Fever - Enteric Fever
 
Malaria
MalariaMalaria
Malaria
 
Malaria ppt.
Malaria ppt.Malaria ppt.
Malaria ppt.
 

More from MebratGebreyesus

1. Existing Practice and Limitations.ppt
1. Existing Practice and Limitations.ppt1. Existing Practice and Limitations.ppt
1. Existing Practice and Limitations.ppt
MebratGebreyesus
 
Parkinson’s Disease.pptx
Parkinson’s Disease.pptxParkinson’s Disease.pptx
Parkinson’s Disease.pptx
MebratGebreyesus
 
seizure III.pptx
seizure III.pptxseizure III.pptx
seizure III.pptx
MebratGebreyesus
 
HTN E & U(1) (1).pptx
HTN E & U(1) (1).pptxHTN E & U(1) (1).pptx
HTN E & U(1) (1).pptx
MebratGebreyesus
 
meningio.pptx
meningio.pptxmeningio.pptx
meningio.pptx
MebratGebreyesus
 
meningitis .pptx
meningitis .pptxmeningitis .pptx
meningitis .pptx
MebratGebreyesus
 
Presentation1.pptx
Presentation1.pptxPresentation1.pptx
Presentation1.pptx
MebratGebreyesus
 
4. Service Organization, Staffing and Dispensing Flow.pptx
4. Service Organization, Staffing and Dispensing Flow.pptx4. Service Organization, Staffing and Dispensing Flow.pptx
4. Service Organization, Staffing and Dispensing Flow.pptx
MebratGebreyesus
 
Gyni presentation.pptx1.pptx1.pptx
Gyni presentation.pptx1.pptx1.pptxGyni presentation.pptx1.pptx1.pptx
Gyni presentation.pptx1.pptx1.pptx
MebratGebreyesus
 
SEMINAR PRESENTATION.pptx dmmm.pptx
SEMINAR PRESENTATION.pptx dmmm.pptxSEMINAR PRESENTATION.pptx dmmm.pptx
SEMINAR PRESENTATION.pptx dmmm.pptx
MebratGebreyesus
 
contraception ppt.ppt
contraception ppt.pptcontraception ppt.ppt
contraception ppt.ppt
MebratGebreyesus
 
Meningitis-Pedi ( by Desalegn D.).pptx
Meningitis-Pedi ( by Desalegn D.).pptxMeningitis-Pedi ( by Desalegn D.).pptx
Meningitis-Pedi ( by Desalegn D.).pptx
MebratGebreyesus
 
Guillain-Barré Syndrome.pptx
Guillain-Barré Syndrome.pptxGuillain-Barré Syndrome.pptx
Guillain-Barré Syndrome.pptx
MebratGebreyesus
 
poising assignment.pptx
poising assignment.pptxpoising assignment.pptx
poising assignment.pptx
MebratGebreyesus
 
DKA & HHS.pptx
DKA & HHS.pptxDKA & HHS.pptx
DKA & HHS.pptx
MebratGebreyesus
 

More from MebratGebreyesus (18)

1. Existing Practice and Limitations.ppt
1. Existing Practice and Limitations.ppt1. Existing Practice and Limitations.ppt
1. Existing Practice and Limitations.ppt
 
Pain.pptx
Pain.pptxPain.pptx
Pain.pptx
 
cld.pptx
cld.pptxcld.pptx
cld.pptx
 
Parkinson’s Disease.pptx
Parkinson’s Disease.pptxParkinson’s Disease.pptx
Parkinson’s Disease.pptx
 
seizure III.pptx
seizure III.pptxseizure III.pptx
seizure III.pptx
 
HTN E & U(1) (1).pptx
HTN E & U(1) (1).pptxHTN E & U(1) (1).pptx
HTN E & U(1) (1).pptx
 
meningio.pptx
meningio.pptxmeningio.pptx
meningio.pptx
 
GBS UPDATE.pptx
GBS UPDATE.pptxGBS UPDATE.pptx
GBS UPDATE.pptx
 
meningitis .pptx
meningitis .pptxmeningitis .pptx
meningitis .pptx
 
Presentation1.pptx
Presentation1.pptxPresentation1.pptx
Presentation1.pptx
 
4. Service Organization, Staffing and Dispensing Flow.pptx
4. Service Organization, Staffing and Dispensing Flow.pptx4. Service Organization, Staffing and Dispensing Flow.pptx
4. Service Organization, Staffing and Dispensing Flow.pptx
 
Gyni presentation.pptx1.pptx1.pptx
Gyni presentation.pptx1.pptx1.pptxGyni presentation.pptx1.pptx1.pptx
Gyni presentation.pptx1.pptx1.pptx
 
SEMINAR PRESENTATION.pptx dmmm.pptx
SEMINAR PRESENTATION.pptx dmmm.pptxSEMINAR PRESENTATION.pptx dmmm.pptx
SEMINAR PRESENTATION.pptx dmmm.pptx
 
contraception ppt.ppt
contraception ppt.pptcontraception ppt.ppt
contraception ppt.ppt
 
Meningitis-Pedi ( by Desalegn D.).pptx
Meningitis-Pedi ( by Desalegn D.).pptxMeningitis-Pedi ( by Desalegn D.).pptx
Meningitis-Pedi ( by Desalegn D.).pptx
 
Guillain-Barré Syndrome.pptx
Guillain-Barré Syndrome.pptxGuillain-Barré Syndrome.pptx
Guillain-Barré Syndrome.pptx
 
poising assignment.pptx
poising assignment.pptxpoising assignment.pptx
poising assignment.pptx
 
DKA & HHS.pptx
DKA & HHS.pptxDKA & HHS.pptx
DKA & HHS.pptx
 

Recently uploaded

Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
DR SETH JOTHAM
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 

Recently uploaded (20)

Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 

MALARIA.pptx

  • 2. Learning objective  Definition of malaria and types of malaria parasites  Epidemiology of malaria  Risk factor of malaria  Life cycle of malaria  Incubation period of the parasite  Pathophysiology of malaria  Signs and symptoms of malaria  Laboratory diagnosis of malaria  Treatment and prevention of malaria  Complication of malaria
  • 3. What is malaria ? • Malaria is a serious or life threatening disease that spreads when you’re bitten by a Anopheles mosquito infected by tiny parasites. When it bites, the mosquito injects malaria parasites into your bloodstream. Malaria is caused by the parasites, not by a virus or by a type of bacterium. • If it isn’t treated, malaria can cause severe health problems such as seizures, brain damage, trouble breathing, organ failure and death.
  • 4. Cont… • Is an infection of liver and RBCs caused by protozoan parasites of the genus plasmodium. Malaria is caused by 5 species of plasmodium: • P. falciparum (the most common and dangerous). • P. vivax (the most common) • P. ovale • P. malariae • P. knowlesi
  • 5. Epidemiology • It is reported that Plasmodium vivax is more prevalent in India, Pakistan, Bangladesh, Sri Lanka, and Central America, • whereas Plasmodium falciparum is predominant in Africa, Haiti, Dominican Republic, the Amazon region of South America, and New Guinea. • Most of the infections with Plasmodium ovale occur in Africa, and the distribution of Plasmodium malariae is considered worldwide.
  • 6. Cont… • The commonest causes of malaria in Ethiopia are Plasmodium falciparum and Plasmodium vivax. P. falciparum causes virtually all the severe forms of malaria. • More than 50% of the total population in Ethiopia is exposed to the risk of malaria infection. Every year, four to five million people are affected by malaria while a major epidemic occurs every five to eight years.
  • 7. Risk factor for malaria • Living or traveling in a region where malaria is present. • Traveling to area where malaria is common: - Without taking medicine to prevent malaria. - Being outdoors, especially in rural areas - Not taking steps to protect yourself from mosquito bites. • Pregnant women. • Children under 5 years of age. • Patients with HIV/AIDS.
  • 8. Lifecycle of Plasmodium • 2 stages 1) Sexual phase in the mosquito – sporogony 2) Asexual phase in humans A, Exoerthrocytic phase ( liver stage ) B, Erythrocytic phase ( blood stage ) • The infectious stage of malaria - Sporozoite (found in the salivary glands of female mosquitoes).
  • 9. Exoerthrocytic Phase • Sporozoites enters the hepatocytes and become merozoites . Merozoites replicates asexually forming a schizont which eventually bursts. • In p. ovale and p. vivax, some sporozoites do not undergo asexual replication and enter a dormant phase known as hypnozoites which reactivate later resulting in a relapse.
  • 10. Erythrocytic Phase • Merozoites release from hepatocytes invade erythrocytes, undergoes a trophic period then replicates in it asexually. • It later bursts releasing merozoites which infect more cells. • The release of merozoites is what causes malarial paroxyms.
  • 11. Sporogony • Trophozites in RBC’s undergo a sexual cycle which differentiates into gametocytes and are then ingested by a mosquito. • In the mosquito: Gametocytes become gametes which fuse to become a zygote in the mosquitos gut which then develops into an ookinete then into an oocyte. • The oocyte divides asexually, ruptures and releases sporozoites which infects the salivary gland and is what is injected into the host.
  • 12.
  • 13. Incubation period • Following the infective bite by the Anopheles mosquito, a period of time (the “incubation period”) goes by before the first symptoms appear. The incubation period in most cases varies from 7 to 30 days.
  • 14. Incubation period of the parasite SPECIES INCUBATION PERIOD ( LIVER CYCLE ) P. falciparum 7-14 days p. vivax 12-17 days( with relapse up to 3years ) p. ovale 9-18 days ( with relapse up to 20 years p. malaria 13-40 days
  • 15. Cont.. • The time between the fever episodes can be characteristics of the infecting plasmodium species SPECIES Duration of fever (erythrocytic cycle ) P. falciparum 36-48hr, Malignant tertian fever p. vivax 48hr, Benign tertian fever p. ovale 48hr, Ovale tertian fever p. malaria 72hr, Quartan fever
  • 16. Pathophysiology of malaria • New merozoites are released from the RBCs at intervals of approximately 48h for P.vivax, P.ovale and P.falciparum and 72h for P.malaria. The episodic shaking, chills, and fever coincide with this release. • The parasites destroy large numbers of infected RBC, thereby causing a hemolytic anemia.
  • 17. Cont.. • A characteristic brown malaria pigment derived from hemoglobin, called hemozoin is released from ruptured RBCs and produces discoloration of the spleen, liver, lymph nodes and bone marrow. • Activation of defense mechanisms in the host leads to a marked hyperplasia of mononuclear phagocytes, producing massive splenomegaly and occasional hepatomegaly.
  • 18. Common symptoms • High temperature 38c or above • Feeling hot or shivery • Headaches • Vomiting • Diarrhea • Muscle pain • Generally feeling unwell
  • 19. CLINICAL FEATURE OF UNCOMPLICATED MALARIA • Fever, chills, rigors, sweating • Headache, generalized body and joint pain (myalgia and arthralgia) • Nausea and/or vomiting, loss of appetite, abdominal pain (especially in children) • Irritability and refusal to feed (in infants), flu-like symptoms, • Fever, usually above 38°C • hepatosplenomegaly
  • 20. INVESTIGATIONS AND DIAGNOSIS Investigations • Microscopy-thick and thin blood films for malaria parasites • Rapid diagnostic tests (RDT)-if microscopy is unavailable • CBC Diagnosis • The diagnosis of malaria can be confirmed when malaria parasites are demonstrated in the blood films (thick or thin) or with Rapid Diagnostic Test (RDT).
  • 21. Cont.. • Blood film is also helpful to estimate the degree of parasitemia, which is very useful not only to predict severity but gauge response to treatment. • If neither microscopy nor rapid tests are available, diagnosis should be made on the basis of clinical presentation. • Clinical diagnosis of malaria is made in a patient who has fever or history of fever in the past 48 hours and lives in malaria-endemic areas or has a history of travel within the last 30 days to malaria-endemic areas
  • 22. Treatment Objectives • Prevent uncomplicated malaria from progressing to severe form • Improve societal productivity • Prevent death from malaria complication • Prevent the development and transmission of drug resistance • Decrease malaria transmission to others
  • 23. SUPPORTIVE TREATMENT FOR UNCOMPLICATED MALARIA • Fever management (axillary temp record of ≥37.50C) Antipyretics − Paracetamol (acetaminophen) 15 mg/kg (for adults 1000mg) every 4-6 hours, given orally or as a suppository. Fanning and tepid sponging • Check for signs of severity • Assess the ability to tolerate oral medication. • If there is any sign of severity or the patient is unable to tolerate oral medications admit patients for parenteral treatment.
  • 24. PHARMACOLOGIC • P. falciparum: First line:Artemether +Lumefantrine(AL), fixed dose combination (20mg + 120mg) for 3 days + a single dose primaquine phosphate (15mg base P.O). • First line for pregnant women in the first trimester: quinine
  • 25. Cont.. • P. vivax o Chloroquine phosphate 25 mg/kg given in divided doses over three days − 1 g (4 tablets) initially, then 500mg (2tablets) in 6 hours, it is then followed by 500mg (2ablets), PO, daily for 2 days. OR − 1g (4 tablets) at 0 and 24 hours. It is followed by 500mg (2 tablets) at 48 hrs. o Primaquine phosphate 15mg base, PO, daily for 14 days for all patients after completing the three days of chloroquine.
  • 26. Mixed infections (P. falciparum and P. vivax) • Artemisinin based combination therapies (like AL for 3 days) should be used for mixed (falciparum and vivax) infections, followed by 14-day primaquine phosphate. • Avoid primaquine in pregnant, breast-feeding mothers less than 6 months infants, infants under six months of age.
  • 27. TREATMENT FAILURE • Consider treatment failure in a patient with malaria who was treated for malaria in the past 28 days. • The cause might be drug resistance, poor adherence or inadequate drug exposure (i.e. from under-dosing, vomiting, drug interaction, misdiagnosis or substandard medicines. • If the cause for treatment failure identified early (e.g. anti-malarial drug is vomited), address the cause and reinstituted treatment with the first line anti-malarial drug;
  • 28. Cont… • If a P. falciparum or P. vivax-infected patient returns with fever or history of fever between days 4 to 28 of treatment, microscopic blood examination should be made (do not use RDTs). • If parasites are detected, administer second-line drug, e.g., quinine tablets; • If blood smear is negative and no other obvious causes found, reevaluate,or refer • For treatment failure after 28 days, first line antimalarial drugs should be used.
  • 29. COMPLICATED (P. FALCIPARUM ) MALARIA • Delayed presentation, delay in diagnosis or inappropriate treatment of uncomplicated malaria can lead to the rapid development of severe or “complicated malaria”. • It is commonly occurring in children under 5 years of age, pregnant women and non-immune individuals. Severe malaria may lead to death unless it is diagnosed early and appropriately managed.
  • 30. CLINICAL FEATURES • Inability to take in fluids (or breast milk in children) • Repetitive vomiting • Dark or ‘cola-colored’ urine/ hemoglobinuria • Difficulty in breathing , • Generalized convulsions, • Altered consciousness, confusion, delirium, convulsions, coma • Circulatory collapse or shock (cold limbs, weak rapid pulse) • Tachypnea, respiratory distress and/or cyanosis • Hyperpyrexia (axillary temperature >38.5°C) • Hypoglycemia • Severe anemia (Hb < 6 g/dl) or extreme pallor (severe anemia)
  • 31. INVESTIGATIONS AND DIAGNOSIS Investigation • Microscopy-thick and thin blood films for malaria parasites • Rapid diagnostic test (RDT)-if microscopy is unavailable • Hemoglobin, hematocrit, CBC • Blood glucose (RBS) • Blood grouping and cross-matching • BUN and creatinine
  • 32. Cont.. Diagnosis • The diagnosis of severe malaria is based on clinical features and confirmed with laboratory testing. While confirmation of the diagnosis is necessary treatment must be started promptly and not withheld while confirming the diagnosis.
  • 33. TREATMENT OF SEVERE AND COMPLICATED P. FALCIPARUM MALARIA Objectives • Administer medicines parenterally to ensure adequate blood-serum concentrations of the medicine and rapid clearance of parasitemia • Provide urgent treatment for life threatening problems e.g., convulsions, hypoglycemia, dehydration, renal impairment • Prevent death from malaria
  • 34. Cont.. Non pharmacologic • Clear and maintain the airway. • Open IV line for 8 hours of intravenous fluids including diluents for antimalarial medicine, glucose therapy and blood transfusion. • Make rapid clinical assessment. • Weigh the patient and calculate dosage. • Exclude or treat hypoglycemia (more so in pregnant women and children). • Assess state of hydration. • Measure and monitor urine output.
  • 35. Pharmacologic General principles of treatment o It is a medical emergency. o Parenteral administration required (Artesunate >quinine) o Also involves multiple supportive treatment measures
  • 36. First line • Artesunate, 2.4mg/Kg IV or IM given on admission (time = 0), then repeat at 12 hours, and 24 hours, then once a day for up to 5 days. OR • If artesunate is unavailable: Artemether, IM 3.2mg/kg loading dose on the first day followed by 1.6mg/kg daily for five days OR • If artesunate and artemether are unavailable: Quinine hydrochloride  Quinine hydrochloride loading dose: 20mg/kg in 500ml of 5% dextrose or normal saline over 4 hours (4ml/minute). The pediatric loading dose is the same but the fluid replacement must be based on body weight.
  • 37. DOSING GUIDELINES FOR ANTIMALARIAL DRUGS • Artesunate is dispensed as a powder of Artesunic acid. • The 60mg vial of artesunate must be reconstituted in two steps: First: sodium bicarbonate solution (Provided separately along with the vial) Second: with 5ml of 5% glucose (D5W) solution. • Full reconstitution results in either 6ml (for intravenous use, with a concentration of 10mg/ml) or 3ml (for intramuscular injection, with a concentration of 20mg/ml).
  • 38. HEMATOLOGIC COMPLICATIONS (INCLUDING SEVERE ANEMIA AND COAGULOPATHY) Anemia • Indication for transfusion − If hematocrit is below 15% (Hg <5g/dl) in a normally hydrated child or adult. − Anemia with shock or evidence heart failure, metabolic acidosis (deep labored breathing or high parasitemia (>20% of RBCs parasitized) • Volume of transfusion: 10 ml/Kg of packed RBC or 20 ml whole blood/ kg of body weight. For adults it is equivalent to 2-3 units of packed RBC or 2-3 units of whole blood. • The volume of all blood products should be included in the overall fluid balance. The patient should be closely monitored during the blood transfusion.
  • 39. Cont.. Bleeding tendency: • Check for evidence of DIC (if laboratory tests are available): platelet count, PT/INR, and PTT Management: Transfusion of platelet and fresh frozen plasma or fresh whole blood (if platelet and fresh frozen plasma are not available).
  • 40. ACUTE RENAL FAILURE (ACUTE KIDNEY INJURY) • Persistent oliguria, despite adequate correction of dehydration or hypotension: o <17 ml/hour in adults (<200ml in 12 hours or <400ml in 24 hours); <0.3 ml/kg/hour in children. OR • Elevated serum creatinine: increase in serum creatinine more than twice (two fold) from baseline. Management: correct dehydration, if there is any evidence of hypovolemia. Avoid over hydration (fluid overload). If oliguria persists, refer to a facility with dialysis service.
  • 41. HYPOGLYCEMIA: • Suspect in any patient who deteriorates suddenly, decreased level of consciousness or convulsions. • Threshold for intervention among children <5 years is <3 mmol/L (<54mg/dl); children ≥5 years and adults are <2.2 mmol/L (<40 mg/dl). Management • IV dextrose: initial bolus − 40% dextrose for children: 1ml/kg/dose, diluted with equal volume of NS, give slowly to avoid irritation of vein and extravasation. − 40% dextrose for adults: 80ml (4 vials of 20ml preparation) diluted with equal volume of NS, administer slowly.
  • 42. NEUROLOGIC COMPLICATIONS (INCLUDE ALTERED SENSORIUM, SEIZURE, AND COMA): • Management of convulsions: o Ensure the patient is in a safe environment to avoid injuries o Position the patient laterally (sideways) to protect the airways o Diazepam − Children: 0.15 mg/kg body weight IV or 0.5 mg/kg body rectally − Adults: 0.15 mg/kg body weight IV (maximum 10 mg) • Management of coma o Position the patient on the sides, change positions every 2 hours, correct hypoglycemia and regularly check blood sugar levels.
  • 43. Prevention • Avoid mosquito bites: using mosquito repellants, insectides, using mosquito nets, wearing long sleeves and trousers and window screens. • chemoprophylaxis for travellers and pregnant women. For all species of Plasmodium is chloroquine phosphate 300 mg (base) once weekly beginning 1 week prior to departure and continued for 4 weeks after leaving an endemic area. The pediatric dose is (5 mg) (base) per kilogram of body weight (maximum: 300 mg). If the traveller is going to places where there is a chloroquine resistance : Mefloquine, 5mg base per kg weekly (1tablet for adults >50kg, begin > 2weeks before travel to endemic area), take weekly on the same day while in the area and for 4 weeks after leaving the area.
  • 44. Reference • Dipiro pharmacotherapy : a pathophysiology approach 7th edition • Ministry of health - Ethiopian standard treatment guidelines for general hospital 4th edition 2021 • Centers for disease control and prevention (CDC)– about malaria